Skip to content
10-Q

Quarterly Report

Maravai LifeSciences Holdings, Inc. MRVI

0001823239-25-000107

← back to feed
Filed
Aug 11, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q2 2025 · Jun 30, 2025 144.24M sh
Shares Diluted Q2 2025 · Jun 30, 2025 143.83M sh
Shares Diluted Q2 2025 · Jun 30, 2024 135.84M sh
Shares Diluted Q2 2025 · Jun 30, 2024 134.09M sh
Capex Q2 2025 · Jun 30, 2025 $8.11M
Capex Q2 2025 · Jun 30, 2024 $15.22M
Operating Cash Flow Q2 2025 · Jun 30, 2025 −$19.66M
Operating Cash Flow Q2 2025 · Jun 30, 2024 $8.97M
Long Term Debt Q2 2025 · Jun 30, 2025 $288.44M
Long Term Debt Q2 2025 · Dec 31, 2024 $290.49M
Short Term Debt Q2 2025 · Jun 30, 2025 $5.44M
Short Term Debt Q2 2025 · Dec 31, 2024 $5.44M
Cash And Equivalents Q2 2025 · Jun 30, 2025 $269.91M
Cash And Equivalents Q2 2025 · Dec 31, 2024 $322.4M
Stockholders Equity Q2 2025 · Jun 30, 2025 $265.86M
Stockholders Equity Q2 2025 · Dec 31, 2024 $325.29M
Current Liabilities Q2 2025 · Jun 30, 2025 $69.68M
Current Liabilities Q2 2025 · Dec 31, 2024 $56.97M
Total Liabilities Q2 2025 · Jun 30, 2025 $428.98M
Total Liabilities Q2 2025 · Dec 31, 2024 $431.04M
Current Assets Q2 2025 · Jun 30, 2025 $359.76M
Current Assets Q2 2025 · Dec 31, 2024 $429.15M
Total Assets Q2 2025 · Jun 30, 2025 $896.97M
Total Assets Q2 2025 · Dec 31, 2024 $1.01B
Eps Diluted Q2 2025 · Jun 30, 2025 −$0.27
Eps Diluted Q2 2025 · Jun 30, 2025 −$0.48
Eps Diluted restated Q2 2025 · Jun 30, 2024 −$0.07
Eps Diluted restated Q2 2025 · Jun 30, 2024 −$0.16
Eps Basic Q2 2025 · Jun 30, 2025 −$0.27
Eps Basic Q2 2025 · Jun 30, 2025 −$0.48
Eps Basic restated Q2 2025 · Jun 30, 2024 −$0.07
Eps Basic restated Q2 2025 · Jun 30, 2024 −$0.16
Sga Expense Q2 2025 · Jun 30, 2025 $38.58M
Sga Expense Q2 2025 · Jun 30, 2025 $78.14M
Sga Expense Q2 2025 · Jun 30, 2024 $40.56M
Sga Expense Q2 2025 · Jun 30, 2024 $81.44M
Rd Expense Q2 2025 · Jun 30, 2025 $4.88M
Rd Expense Q2 2025 · Jun 30, 2025 $9.77M
Rd Expense restated Q2 2025 · Jun 30, 2024 $4.92M
Rd Expense restated Q2 2025 · Jun 30, 2024 $9.96M
Net Income Q2 2025 · Jun 30, 2025 −$39.59M
Net Income Q2 2025 · Jun 30, 2025 −$69.54M
Net Income restated Q2 2025 · Jun 30, 2024 −$9.79M
Net Income restated Q2 2025 · Jun 30, 2024 −$21.87M
Operating Income Q2 2025 · Jun 30, 2025 −$66.28M
Operating Income Q2 2025 · Jun 30, 2025 −$115.44M
Operating Income restated Q2 2025 · Jun 30, 2024 −$13.44M
Operating Income restated Q2 2025 · Jun 30, 2024 −$32.3M
Cost Of Revenue Q2 2025 · Jun 30, 2025 $39.63M
Cost Of Revenue Q2 2025 · Jun 30, 2025 $78.75M
Cost Of Revenue restated Q2 2025 · Jun 30, 2024 $38.58M
Cost Of Revenue restated Q2 2025 · Jun 30, 2024 $76.92M
Revenue Q2 2025 · Jun 30, 2025 $47.4M
Revenue Q2 2025 · Jun 30, 2025 $94.25M
Revenue restated Q2 2025 · Jun 30, 2024 $69.42M
Revenue restated Q2 2025 · Jun 30, 2024 $133.6M